Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAdOx1 RVF vaccine in healthy Ugandan adults
NCT04672824Phase 1Completed
- Sponsor
- University of Oxford
- Start
- May 2022
- Primary completion
- Dec 2022
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of ChAdOx1 RVF in Rift Valley fever (RVF) (4 arms), sponsored by University of Oxford. Primary endpoints: Adverse Events at 3 months and Change in baseline Adverse Events at 3 months. Started May 2022; status: completed.
02
Drugs
ChAdOx1 RVF
03
Conditions
Rift Valley fever (RVF)
Beyond the preview
Go deeper on NCT04672824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672824.